Results 91 to 100 of about 251,092 (150)

Cutaneous involvement in multiple myeloma. A rare entity. [PDF]

Clin Case Rep
Rapparini L, Pileri A, Robuffo S, Agostinelli C, La Placa M.   +4 more
europepmc   +1 more source

Corrigendum: Lipid have a direct effect on multiple myeloma: a Mendelian randomization study. [PDF]

Front Oncol
Zhong Y, Li Y, Sun W, Xiao M.
europepmc   +1 more source

Predicting progression events in multiple myeloma from routine blood work. [PDF]

NPJ Digit Med
Ferle M, Grieb N, Kreuz M, Ader J, Goldschmidt H, Mai EK, Bertsch U, Platzbecker U, Neumuth T, Reiche K, Oeser A, Merz M.   +11 more
europepmc   +1 more source

Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives. [PDF]

J Bone Oncol
Lungu O, Toscani D, Giuliani N.
europepmc   +1 more source

Current Treatment Strategies for Multiple Myeloma at First Relapse. [PDF]

J Clin Med
Mavrothalassitis E, Triantafyllakis K, Malandrakis P, Gavriatopoulou M, Kleber M, Ntanasis-Stathopoulos I.   +5 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

Correction: Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. [PDF]

Signal Transduct Target Ther
Liu X, Cao W, Qin S, Zhang T, Zheng J, Dong Y, Ming P, Cheng Q, Lu Z, Guo Y, Zhang B, Liu Y.   +11 more
europepmc   +1 more source